Cargando…
Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017
BACKGROUND: Treatment with direct-acting antiviral agents (DAAs) offers an opportunity to eliminate hepatitis C virus (HCV) endemic among people who inject drugs (PWID) and people enrolled in opioid agonist therapy (OAT) programs. The objective of this study was to estimate and to compare HCV treatm...
Autores principales: | Aas, Christer F., Vold, Jørn Henrik, Skurtveit, Svetlana, Odsbu, Ingvild, Chalabianloo, Fatemeh, Lim, Aaron G., Johansson, Kjell Arne, Fadnes, Lars Thore |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325258/ https://www.ncbi.nlm.nih.gov/pubmed/32605625 http://dx.doi.org/10.1186/s13011-020-00286-2 |
Ejemplares similares
-
Potentially addictive drugs dispensing to patients receiving opioid agonist therapy: a register-based prospective cohort study in Norway and Sweden from 2015 to 2017
por: Vold, Jørn Henrik, et al.
Publicado: (2020) -
Dispensation of attention deficit hyperactivity disorder (ADHD) medications in patients receiving opioid agonist therapy; a national prospective cohort study in Norway from 2015 to 2017
por: Vold, Jørn Henrik, et al.
Publicado: (2020) -
Too much or too little opioids to patients receiving opioid agonist therapy in Norway (2013–2017): a prospective cohort study
por: Vold, Jørn Henrik, et al.
Publicado: (2020) -
Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017
por: Vold, Jørn Henrik, et al.
Publicado: (2020) -
On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017
por: Aas, Christer Frode, et al.
Publicado: (2020)